Pfizer and BioNTech say regulatory review for Covid-19 vaccine could be as early as October

Pfizer's Covid-19 vaccine candidate, which it is producing jointly with BioNTech, could be ready for regulatory review by October, as the companies released more encouraging data from an earlier trial.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.